Kornimate/medical-research-clean huggingface dataset:
the peer-delivered body project for young women in high school

Conditions: Eating Disorders in Adolescence

Summary: this study will evaluate the impact of the body project (a dissonance-based program designed to address body image concerns and prevent eating disorders) on key eating disorder risk factors and relevant social and self-constructs at three time-points (pre, post, and one-year follow-up). young women will be recruited from two high schools and will be randomized to receive the body project or to the control group. the body project will be facilitated by college-aged women.

preventive models that can avert the onset of eating disorders and innovative delivery methods that increase engagement with care offer a promising approach to improving the mental health and wellness of young women. this study aims to implement and evaluate the body project, a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders with high school young women using a peer delivery model. this study will evaluate the impact of the body project on key eating disorder risk factors and relevant social and self-constructs at three time-points (pre, post, and one-year follow-up). young women will be recruited from two high schools and will be randomized to receive the body project program or to the control group. the body project will be facilitated by college-aged young women who have been trained to deliver the body project.

Eligibility criteria:
inclusion criteria: - female high school student exclusion criteria: - previous participation in the body project program

Keywords: eating disorder prevention body project female adolescence peer delivery
effects of serotonin agonist citalopram on multimodal esophageal stimulation in healthy volunteers

Conditions: Gastroesophageal Reflux

Summary: to investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity.


Eligibility criteria:
inclusion criteria: * hv aged between 18 - 60 years exclusion criteria: * history of psychiatric disease or a positive first degree psychiatric family history * pregnancy or lactation * concomitant administration of any centrally activating medication (anti-depressive medication, hypnotics, sedatives, anxiolytics, ...) * medication affecting esophageal motility * significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic) * prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure * history of gastrointestinal disease
new health devices to improve adherence to physical activity in overweight inactive adults

Conditions: Cardiovascular Diseases; Obesity

Summary: the purpose of this study is to test in overweight and inactive adults whether the new pai ehealh app leads to better adherence to a physical activity regimen than the wearable step counter app from the market leader fitbit, and to evaluate if improved adherence will be reflected in a better cardiovascular profile in this group.


Eligibility criteria:
inclusion criteria: * body mass index \> 25 * self reported exercise one time or less per week exclusion criteria: * inability to use a smartphone * illness or disabilities that preclude or hinder completion of the study * cancer that makes participation impossible or exercise contraindicated (considered individually, in consultation with physician) * test results indicating that study participation is unsafe * participation in other studies conflicting with participation in this study * symptomatic valvular, hypertrophic cardiomyopathy, unstable angina, primary pulmonary hypertension, uncontrolled hypertension, heart failure or sever arrhythmia * diagnosed dementia * chronic communicable infectious diseases * bariatric surgery * medication for thyroid disease, diabetes, blood pressure or lipid lowering medication

Keywords: healthy volunteers patient compliance exercise motivation
rehabilitation required due to clinical disorders after severe covid-19 infection

Conditions: Covid19

Summary: due to the emergence of an epidemic cluster in mulhouse, a city located 100 km south of strasbourg, alsace was one of the first french regions to be affected by the coronavirus (sars-cov-2 or covid-19). as a result, all hospitals in the region, including both strasbourg university hospitals, had to deal with the epidemic wave earlier and more intensely than the rest of france. at the time of writing this article, 6 weeks after the start of the epidemic, we have counted 998 hospital deaths in our region, i.e., an intrahospital mortality rate linked to covid-19 of 5.3 deaths per 10,000 inhabitants (https://dashboard.covid19.data.gouv.fr/). currently, our intensive care unit still has a large number of patients hospitalized for covid-19. some of these patients have severe damage to one or more organs, and in particular a neurological or respiratory deficit suggesting that they will need post-resuscitation rehabilitation. the primary aim is to assess the neurological disorder after severe sars-cov-2 infection and the second is the respiratory impairment evaluation.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * patient hospitalized in surgical intensive care at the new civil hospital between february 24 and april 15, 2020. * patient with a sars-cov-2 infection documented by rt-pcr or with lesions suggestive on chest ct. * patient who has given his consent for the use of his data for the purposes of this research exclusion criteria: * patient without documentation of sars-cov-2 infection (rt-pcr or chest scanner) * patient who expressed his opposition to participating in the study * subject under safeguard of justice * subject under guardianship or guardianship

Keywords: rehabilitation sars-cov-2 covid-19 neurological function respiratory disorder intensive care unit
assessing mucociliary clearance and airway liquid volume in the cf airway

Conditions: Cystic Fibrosis

Summary: the objective of this study is to determine the effect of airway surface liquid (asl) volume on mucociliary clearance in cystic fibrosis (cf). a two-isotope nuclear medicine technique will be utilized. this pilot trial will include the imaging of n=7 cf subjects and n=7 healthy subjects. the trial will include one study visit per subject that will take approximately 3 hours. hypothesis: the simultaneous imaging of both a "floating" and a "penetrating" radioisotope tag will allow the relative effect of airway surface liquid volume on mucociliary clearance to be determined when evaluated in cf and normal subjects.

improper function of the mucociliary clearance system in the cystic fibrosis (cf) lung is a major factor contributing to the chronic respiratory manifestations of the disease. normally this host defense mechanism removes inhaled pathogens and toxins from the inner surfaces of the lung. in cf, mutations in the cf gene result in dysfunction of the cystic fibrosis transmembrane conductance regulator (cftr) ion channel on the cells that line the airway epithelium, causing improper fluxes of ions such as sodium, chloride, and bicarbonate. the so called "low volume" hypothesis of cf pathogenesis contends that the liquid lining the airways becomes very thin and viscous due to abnormal absorption of sodium from the airways, which draws water out of the airways, partially or totally defeating mucociliary clearance. the rate at which the mucociliary system clears materials from the lungs can be quantified using a nuclear medicine test called a mucociliary clearance scan. this study pilots a new variation of the mucociliary clearance scan that uses both "floating" and "penetrating" radioisotope tags. the difference in clearance between these tags will provide information on how airway surface liquid volume affects mucociliary clearance. this pilot trial will include the imaging of n=5 cf subjects and n=5 healthy subjects.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms (cf subjects only) * clinically stable as determined by the investigator (pulmonologist) exclusion criteria: * reactive airways disease * tobacco smokers * positive urine pregnancy test on the day of testing * fev1p value of \< 30% * sao2 \< 92%, or if they require supplemental oxygen. * subjects receiving other radioisotope treatments within the last 2 weeks will be excluded. * normal subjects with any history of lung disease will be excluded. * women currently breastfeeding an infant.

Keywords: cystic fibrosis mucociliary clearance nuclear medicine
a trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiency

Conditions: Adult Growth Hormone Deficiency; Endocrine System Diseases; Hormone Deficiency

Summary: this is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of lonapegsomatropin administered once-weekly. the study participants are adults (males and females) with confirmed growth hormone deficiency (ghd) having completed the treatment period in study tch-306 (foresight).


Eligibility criteria:
inclusion criteria: * signing of the trial specific informed consent * completion of the treatment period and visit 7 assessments of trial tch-306, including collection and upload of visit 7 dxa scan * fundoscopy at visit 7 in trial tch-306 without signs/symptoms of intracranial hypertension or diabetic retinopathy stage 2 / moderate or above exclusion criteria: * diabetes mellitus if any of the following are met: 1. poorly controlled diabetes, defined as hba1c higher than 7.5% according to central laboratory at visit 6 in trial tch-306 2. use of diabetes mellitus drugs other than metformin and/or dipeptidyl peptidase-4 (dpp-4) inhibitors * active malignant disease or history of malignancy. exceptions are: 1. resection of in situ carcinoma of the cervix uteri 2. complete eradication of squamous cell or basal cell carcinoma of the skin * known history of hypersensitivity and/or idiosyncrasy to the investigational product (somatropin or excipients) * female who is pregnant, plans to become pregnant, or is breastfeeding * female participant of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) not willing throughout the trial to use contraceptives as required by local law or practice. details included in appendix 4/section 10.4 of the protocol * male participant not willing throughout the trial to use contraceptives as required by local law or practice. details included in appendix 4/ section 10.4 of the protocol * any disease or condition that, in the judgement of the investigator, may make the participant unlikely to comply with the requirements of the protocol or any condition that presents undue risk from the investigational product or trial procedures

Keywords: human growth hormone hgh rhgh ghd adult growth hormone deficiency long acting growth hormone lonapegsomatropin prodrug growth hormone replacement therapy sustained release growth hormone growth hormone deficiency transcon hgh skytrofa
effects of amlodipine/benazepril in reducing left ventricular hypertrophy in patients with high risk hypertension

Conditions: Hypertension; Left Ventricular Hypertrophy

Summary: left ventricular hypertrophy (lvh) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without lvh. reduction of left ventricular mass (lvm) with antihypertensive agents is associated with improved clinical outcome. this study will evaluate the effects of amlodipine/benazepril in reducing lvm in patients with high risk hypertension.


Eligibility criteria:
inclusion criteria: * males or female patients ≥ 55 years of age * lvh as confirmed by echocardiogram * patients with high risk hypertension, currently treated or already taking antihypertensive medication exclusion criteria: * renal artery stenosis * symptomatic heart failure or known ejection fraction \< 40% * myocardial infarction or stroke within 6 months * presence of cranial aneurysm clips, coronary artery metal stents and pacemakers * pregnant or lactating females * cancer within the last 5 years

Keywords: hypertension left ventricular hypertrophy
utility of digital dermoscopy in the skin cancer clinic

Conditions: Skin Cancer; Dermatology/Skin - Other

Summary: this feasibility study aims to evaluate the use of the barco nv digital dermatoscope (non-ce marked device) in the skin cancer clinic. all eligible patients attending the dermatology outpatient skin cancer clinic will be invited to participate. patients who consent to the study will undergo standard care which will include medical photography of skin lesion(s) and appropriate management as determined by the consultant dermatologist in clinic. in addition to standard care, patients will undergo photography of the same lesion(s) using the barco nv digital dermatoscope. there will be no other intervention and no additional hospital visits in relation to the study. use of the device will not influence the clinical management of the patient. a detailed experience questionnaire will be administered to all clinicians using the barco device to explore their opinion on its ease of use and features. all standard macroscopic \& dermoscopic images will be taken by ouh medical illustration department and stored on the 'fotoweb' database (in keeping with current standard practice). trained dermatology consultants, dermatology registrars, research nurses or medical photographers, will take barco nv device images. a database of all barco images will be collected and stored on a dedicated nhs computer separate from the patient clinical record. standard medical photography images will be stored on fotoweb as per standard nhs clinical care. data will be anonymised and collated and then sent securely to barco for further analyses to enable optimization of the barco device and for development of diagnostic algorithms in the future.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * patient presenting with any visible skin lesion for dermatologist review on a body site amenable for optimal photographic imaging * able and willing to comply with all study requirements. * patient with a skin lesion that is clinically diagnosed by a consultant dermatologist as benign or a suspicious skin lesion requiring excisional biopsy for histological diagnosis * patient attending for a 'new' or 'follow-up' consultation exclusion criteria: * patients aged under 18 years old * patients unable to provide informed consent * skin lesions in an anatomical site which is not suitable for photography including genital lesion, hair-bearing site or subungual lesion * maximum size of lesion 25 mm * lesion is at a site where previous surgery was undertaken * lesion on a mucosal site
safety and tolerability of ibi355 in patients with primary sjogren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: this study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ibi355 in primary sjogren's syndrome (pss) patients. this study also aims to evaluate the anti-drug antibody after multiple ascending doses of ibi355 in pss patients.


Eligibility criteria:
inclusion criteria: 1. understand and sign the informed consent form; 2. age ≥ 18 years, male or female； 3. body mass index (bmi) within the range of 18.0 to 28.0 kg/m² (inclusive); 4. meet the 2016 american college of rheumatology (acr)/european league against rheumatism (eular) classification criteria for sjögren's syndrome; 5. positive for anti-sjögren's syndrome a autoantibodies (ssa) and/or anti-sjögren's syndrome b autoantibodies (ssb); 6. unstimulated whole salivary flow rate \> 0 ml/min; exclusion criteria: 1. individuals who have had allergic reactions to any components of ibi355, have allergic diseases, or possess an allergic constitution; 2. those who cannot tolerate frequent venipuncture procedures; 3. participants diagnosed with secondary sjögren's syndrome, or whose clinical symptoms (or laboratory abnormalities) require explanation by another connective tissue disease (such as systemic lupus erythematosus, mixed connective tissue disease, etc.). 4. subjects paticipated in the other clinical trail in 1 month or less than 5 t1/2 since the previous clinical trial (which is longer)； 5. subjects with an infection requiring systemic medication was present within 30 days prior to randomization; 6. hiv-ab、rpr、hcv-ab、hbv、hbeag or hbcab, one of them positive; 7. there have a clinical or imaging evidence that the subject with active tuberculosis, or there is evidence that the subject is in the incubation period for tuberculosis; 6.patients with a history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic disorders and other systemic diseases; 7. subject with a hcg positive; 8.patients with a history of neuropsychiatry or who are considered unfit to participate in this clinical trial; 9.patients with pulmonary interstitial fibrosis, or those requiring combined antifibrotic drug therapy, or those with abnormal lung function that the investigators determined was not suitable for this study; 10. need to use other drugs that could cause xerostomia during the study.
endtidal ethanol in sclerotherapy

Conditions: Ethanol Concentration

Summary: during the ethanol sclerotherapy procedure, the investigators will record doses of and time of ethanol injections and record ethanol concentrations in endtidal breath every 5 minutes. furthermore after every ethanol injection the concentration will be measured every minute for 5 minutes. to do so, the investigators will attach a breath alcohol testing device to the expiratory carbon dioxide measuring unit. since this is the new standard of the university hospital berne all patients undergo the same procedure. there is no study specific intervention. in this study the investigators will only document the breath alcohol levels, doses and timing of ethanol injections. all other data will be obtained from the anesthesia information system. during the two months of the study, the investigators will also record endtidal ethanol concentration after anesthesia in the postoperative care unit discharge from the unit. the intention is to show the correlation between injected ethanol doses and measured endtidal ethanol concentration over the entire time of the intervention.


Eligibility criteria:
inclusion criteria: * undergoing ethanol sclerotherapy at the university hospital berne exclusion criteria: * under the age of 18

Keywords: sclerotherapy ethanol pulmonal hypertension
tazocin intervention study

Conditions: Bacterial Infections

Summary: 1. to determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (esbl) producing e. coli or k. pneumoniae colonization and infection. 2. to determine the acquisition rate of esbl producing e. coli or k. pneumoniae, both pre-and post-intervention in the selected medical centers.


Eligibility criteria:
inclusion criteria: * all patients admitted or transferred to the icu/pulmonary/infection units * patients of either sex, 18 years of age or older patients who stay in units less than 48 hours will not be enrolled.
microneedle patch with botulinum toxin in management of enlarged facial pores

Conditions: Enlarged Pores

Summary: the purpose of this study is to assess the efficacy and safety of microneedle patch with botulinum toxin for improving enlarged pores.


Eligibility criteria:
inclusion criteria: * at least 18 years old and concerned about enlarged pores * have pore size 0.3-0.6 mm * have pore parameter in each other side of faces not different more than 5% exclusion criteria: * any neuromuscular condition * pregnancy or breast feeding * history of allergy : botulinum toxin, topical anesthesia * history of keloid or hypertrophic scar * history of coagulation or receiving medication that causes coagulation disorder * using drugs that have interaction with botulinum toxin * using topical medication that improves enlarged pores in 1 month * taking medication that improves enlarged pores in 1 month * receiving the laser/treatment/chemical peeling in 6 months
development of an artificial intelligence model for optimising therapy in gliomas gliomas

Conditions: Glioma

Summary: artificial intelligence (ai) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.as reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. molecular characterisation is therefore increasingly essential, as is the use of new predictive methods. with this in mind, the aim of this study is to assess, by means of ai algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider ai algorithms for this purpose.

artificial intelligence (ai) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.as reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. molecular characterisation is therefore increasingly essential, as is the use of new predictive methods. with this in mind, the aim of this study is to assess, by means of ai algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider ai algorithms for this purpose.

Eligibility criteria:
inclusion criteria: 1. patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. specimens may result from incisional biopsy and/or surgical resection and/or blood. whole blood is taken for germinal analysis; 2. age \>=18 years; 3. patients must understand and provide written informed consent; 4. life expectancy \>3 months; 5. presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the investigator principal investigator; 6. presence of available and accessible clinical and histopathological data. exclusion criteria: 1. refusal of informed consent; 2. uncooperative patients; 3. presence of other neoplastic diseases in the last 5 years; 4. pregnant and/or breastfeeding women
a trial of grazax in subjects with hayfever

Conditions: Allergy

Summary: the trial is performed to evaluate the efficacy and safety of specific immunotherapy with grazax for treatment of grass pollen induced allergy.


Eligibility criteria:
inclusion criteria: * history of grass pollen allergy * positive skin prick test to grass * positive specific ige to grass exclusion criteria * fev1 \<70% of predicted value